Information  X 
Enter a valid email address

Tiziana Life SciencesPLC Ord3P (TILS)

Date Time Source Announcement
11 Dec 2018 7:00 am
RNS
Exercise of Warrants & Issue of Equity
03 Dec 2018 7:00 am
RNS
Milciclib HCC Phase IIa Trial Enrollment Completed
28 Nov 2018 7:00 am
RNS
Foralumab: Phase 1 Trial with Nasal Administration
27 Nov 2018 7:00 am
RNS
Holding(s) in Company
26 Nov 2018 7:00 am
RNS
Statement re: ADSs
23 Nov 2018 5:00 pm
RNS
Closing of Offering and Total Voting Rights
20 Nov 2018 7:30 am
RNS
Discounted exercise prices of outstanding warrants
  7:00 am
RNS
Offer Pricing, Nasdaq Listing & Loan Conversion
26 Oct 2018 5:30 pm
RNS
Issue of Equity
18 Oct 2018 7:15 am
RNS
Amended Registration Statement filed with the SEC
16 Oct 2018 7:00 am
RNS
Milciclib synergistic activity presented at AASLD
25 Sep 2018 7:00 am
RNS
Tiziana announces Offering & Application to Nasdaq
24 Sep 2018 7:03 am
RNS
Interim Results for Six Months Ended 30 June 2018
  7:00 am
RNS
U.S. FDA Approval IND Nasal Foralumab Phase 1
13 Sep 2018 1:05 pm
RNS
PDMR Dealing
12 Sep 2018 7:00 am
RNS
PDMR dealings
11 Sep 2018 7:00 am
RNS
PDMR Dealing
24 Aug 2018 7:00 am
RNS
PDMR Dealing
21 Aug 2018 7:00 am
RNS
PDMR dealings
20 Aug 2018 7:00 am
RNS
PDMR Dealing
17 Aug 2018 7:00 am
RNS
PDMR Dealing
16 Aug 2018 9:00 am
RNS
Filing of Investigational New Drug application
27 Jul 2018 7:00 am
RNS
US Registration Statement for Proposed Offering
25 Jun 2018 10:49 am
RNS
Result of AGM
07 Jun 2018 7:01 am
RNS
Appointment of Broker
  7:00 am
RNS
Final Results
01 Jun 2018 7:00 am
RNS
Notice of AGM
23 May 2018 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
16 May 2018 7:00 am
RNS
Milciclib Phase 2a Trial - Tolerability Update
01 May 2018 3:00 pm
RNS
Grant of Options - Director Dealing
27 Apr 2018 7:00 am
RNS
Issue of Equity
19 Apr 2018 7:00 am
RNS
Subscription
16 Apr 2018 7:25 am
RNS
License Agreement
09 Apr 2018 8:25 am
RNS
Presentation at ASCO 3 June 2018
05 Apr 2018 7:00 am
RNS
Appointment of Broker
04 Apr 2018 7:00 am
RNS
Appointment of Director
05 Mar 2018 7:00 am
RNS
Placing to raise �600,000 and issue of equity
02 Mar 2018 12:09 pm
RNS
Statement re broker
22 Jan 2018 7:00 am
RNS
Placing
16 Jan 2018 7:00 am
RNS
Placing
15 Dec 2017 7:00 am
RNS
Placing and Issue of Equity
08 Dec 2017 7:00 am
RNS
Milciclib Phase 2a Trial Update
27 Nov 2017 7:00 am
RNS
Placing
23 Nov 2017 7:00 am
RNS
Phase II Clinical Trial Update
20 Nov 2017 7:00 am
RNS
Subscription
29 Sep 2017 7:00 am
RNS
Interim Results for Six Months Ended 30 June 2017
06 Sep 2017 7:00 am
RNS
A Proprietary Oral Formulation of Foralumab
31 Aug 2017 11:07 am
RNS
Grant of options - Director's dealing
16 Aug 2017 7:00 am
RNS
Conversion of outstanding loan notes
28 Jul 2017 7:00 am
RNS
Publication of Research Article on Foralumab
19 Jul 2017 7:00 am
RNS
Initiation of a Phase IIa Clinical Trial
12 Jul 2017 7:00 am
RNS
Proposed changes to CLNs and Warrant Terms
29 Jun 2017 11:21 am
RNS
Result of AGM
12 Jun 2017 7:00 am
RNS
Appointment of Dr Kunwar Shailubhai as CEO
08 Jun 2017 10:02 am
RNS
NOTIFICATION OF MAJOR INTEREST IN SHARES
  8:14 am
RNS
Bcl-3 pre-clinical update and Director's dealing
01 Jun 2017 7:00 am
RNS
2016 Annual Report and Accounts and notice of AGM
23 May 2017 7:00 am
RNS
Financial Results for Year Ended 31 December 2016
24 Apr 2017 7:14 am
RNS
Announces Approval of a Phase II Clinical Trial
 
Headlines
Top categories

21-Jan-2019 04:02 PM

Market Movers - Top risers and fallers between 15:00 and 16:00

Overall Market Futura Medical 11.35 +7.08% Clontarf Energy Ord 0.25p 0.36 +5.80% Oracle Powe ...

Company finder
Forthcoming announcements

a d v e r t i s e m e n t